<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">geriatr</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гериатрической медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Geriatric Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2686-8636</issn><issn pub-type="epub">2686-8709</issn><publisher><publisher-name>Сайт издателя</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37586/2686-8636-2-2026-176-184</article-id><article-id custom-type="elpub" pub-id-type="custom">geriatr-735</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Хирургическое лечение рака легкого IА стадии у пациентов пожилого и старческого возраста: баланс между радикальностью и переносимостью</article-title><trans-title-group xml:lang="en"><trans-title>Surgical treatment of stage IA lung cancer in elderly and senile patients: balance between radicality and tolerability</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1367-4878</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баксиян</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baksiyan</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Баксиян Галуст Александрович</p><p>Москва</p></bio><bio xml:lang="en"><p>Baksiyan Galust Alexandrovich</p><p>Moscow</p></bio><email xlink:type="simple">galust_1983@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5691-5398</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Восканян</surname><given-names>С. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Voskanyan</surname><given-names>S. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">voskanyan_se@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1222-3351</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остапенко</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostapenko</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">ostapenko_vs@rgnkc.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России (Пироговский Университет), ОСП «Российский геронтологический научно-клинический центр»; Медико-биологический университет инноваций и непрерывного образования ФГБУ «Государственный научный центр федеральный медицинский биофизический центр им. А. И. Бурназяна» ФМБА России<country>Россия</country></aff><aff xml:lang="en">Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University; Medical and Biological University of Innovation and Continuous Education of the Federal State Budgetary Institution «State Research Center Federal Medical Biophysical Center named after A. I. Burnazyan» of the Federal Medical and Biological Agency of Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Медико-биологический университет инноваций и непрерывного образования ФГБУ «Государственный научный центр федеральный медицинский биофизический центр им. А. И. Бурназяна» ФМБА России<country>Россия</country></aff><aff xml:lang="en">Medical and Biological University of Innovation and Continuous Education of the Federal State Budgetary Institution «State Research Center Federal Medical Biophysical Center named after A. I. Burnazyan» of the Federal Medical and Biological Agency of Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России (Пироговский Университет), ОСП «Российский геронтологический научно-клинический центр»<country>Россия</country></aff><aff xml:lang="en">Russian Gerontology Research and Clinical Centre, Pirogov Russian National Research Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>25</day><month>04</month><year>2026</year></pub-date><volume>0</volume><issue>2</issue><fpage>176</fpage><lpage>184</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баксиян Г.А., Восканян С.Э., Остапенко В.С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Баксиян Г.А., Восканян С.Э., Остапенко В.С.</copyright-holder><copyright-holder xml:lang="en">Baksiyan G.A., Voskanyan S.E., Ostapenko V.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.geriatr-news.com/jour/article/view/735">https://www.geriatr-news.com/jour/article/view/735</self-uri><abstract><p>Увеличение продолжительности жизни и успехи современной медицины способствуют ежегодному приросту количества людей старше 65 лет. Среди представителей старших возрастных групп заболеваемость большинством онкологических нозологий достигает максимума. Так, рак легкого среди лиц пожилого и старческого возраста является одной из наиболее серьезных проблем здравоохранения во всем мире. С одной стороны, это заболевание является одним из наиболее распространенных и агрессивных, требующих комплексного лечения, а с другой — перед врачами встает сложная дилемма выбора необходимого объема хирургического вмешательства у пожилых людей. С позиции онкологического радикализма минимально допустимым объемом хирургического лечения рака легкого считается лобэктомия. Однако больные пожилого и старческого возраста, отягощенные сопутствующей патологией и гериатрическими синдромами, часто не в состоянии перенести такую операцию, что является поводом для отказа от хирургического вмешательства. В этих случаях назначается альтернативное, т. е. не хирургическое лечение, в большинстве случаев не обладающее достаточным уровнем радикальности, что приводит к частым и скорым рецидивам болезни. В последние годы торакальные хирурги активно изучают вопрос применимости и адекватности сублобарных резекций при злокачественной патологии легкого. Авторы большинства научных исследований подтверждают, что лобэктомия превосходит по эффективности операции меньшего объема и отвечает всем современным требованиям онкологического радикализма. Лишь в редких случаях раннего рака легкого IА стадии сублобарные резекции демонстрируют сопоставимую с лобэктомией эффективность. Несомненными преимуществами редуцированных по объему операций являются меньшая хирургическая травма с сохранением части легочной паренхимы, существенное снижение количества периоперационных осложнений, лучшее качество жизни оперированных больных. Эти преимущества могут быть обоснованным аргументом в пользу сублобарных резекций при раннем раке легкого у коморбидно отягощенных пациентов, а также у больных пожилого и старческого возраста.МАТЕРИАЛЫ И МЕТОДЫ. Поиск научных источников проводился в системах PubMed, Medline и Elibrary. Временной горизонт поиска — 2019–2025 гг. С использованием указанных и иных критериев были проанализированы 177 научных статей, 67 из которых были включены в исследование.</p></abstract><trans-abstract xml:lang="en"><p>Increased life expectancy and advances in modern medicine contribute to an annual increase in the number of people over 65. The incidence of most oncological diseases peaks among older age groups. Lung cancer is one of the most serious public health problems worldwide among the elderly. On the one hand, this disease is one of the commonest and most aggressive, requiring comprehensive treatment. On the other hand, choosing the appropriate surgical intervention for the elderly poses a difficult dilemma. From the perspective of oncological radicalism, lobectomy is considered the minimum acceptable surgical treatment for lung cancer. However, elderly and senile patients with comorbidities and geriatric syndromes often cannot undergo such an operation, which is the reason for refusing surgical intervention. In these cases, alternative non-surgical treatments are prescribed, but in most cases they are not sufficiently radical, leading to frequent and rapid relapses of the disease. Recently, thoracic surgeons have actively studied the applicability of sublobar resections for malignant lung pathology, and most scientific studies confirm that lobectomies are more effective than less extensive procedures. Only in rare cases of early-stage IA lung cancer can sublobar resection demonstrate comparable efficacy with lobectomy. The undoubted advantage of less extensive procedures is less surgical trauma, preservation of a portion of lung parenchyma, significant reduction in perioperative complications and improved quality of life for patients undergoing surgery. This advantage can be a valid argument in favor of sublobar resection for early lung cancer in patients with comorbidities as well as elderly and geriatric patients.MATERIALS AND METHODS: A search for scientific sources was conducted using PubMed, Medline and Elibrary databases. The timeframe for the search was 2019-2025. Based on these and other criteria, 177 articles were analyzed. Of these, 67 met the inclusion criteria.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ранний рак легкого</kwd><kwd>пожилой возраст</kwd><kwd>старческий возраст</kwd><kwd>старческая астения</kwd><kwd>лобэктомия</kwd><kwd>клиновидная резекция</kwd><kwd>анатомическая сегментэктомия</kwd><kwd>комплексная гериатрическая оценка</kwd></kwd-group><kwd-group xml:lang="en"><kwd>early lung cancer</kwd><kwd>elderly age</kwd><kwd>senile age</kwd><kwd>frailty</kwd><kwd>lobectomy</kwd><kwd>wedge resection</kwd><kwd>anatomical segmentectomy</kwd><kwd>comprehensive geriatric assessment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024. Retrieved from https://population.un.org/wpp/?_gl=1*trpirl*_ga*MTg5OTE1MTE3LjE3NzE5Mzc4NjI.*_ga_TK9BQL5X7Z*czE3NzQ5Njc0NzckbzMkZzEkdDE3NzQ5Njc1MjgkajkkbDAkaDA.</mixed-citation><mixed-citation xml:lang="en">United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024. Retrieved from https://population.un.org/wpp/?_gl=1*trpirl*_ga*MTg5OTE1MTE3LjE3NzE5Mzc4NjI.*_ga_TK9BQL5X7Z*czE3NzQ5Njc0NzckbzMkZzEkdDE3NzQ5Njc1MjgkajkkbDAkaDA.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">International Agency for Research on Cancer (IARC). Cancer today. World Health Organization. 2024. Retrieved from https://gco.iarc.who.int.</mixed-citation><mixed-citation xml:lang="en">International Agency for Research on Cancer (IARC). Cancer today. World Health Organization. 2024. Retrieved from https://gco.iarc.who.int.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2023 году (заболеваемость и смертность) / Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. — М. : МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. — илл. — 276 с.</mixed-citation><mixed-citation xml:lang="en">Malignant neoplasms in Russia in 2023 (incidence and mortality). Edited by A. D. Kaprin, V. V. Starinsky, A. O. Shakhzadova. 2024. Moscow : P. A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, ill. 276 p. (In Russ.). ISBN 978-5-85502-298-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chow R., Lage D. E., Williams G. R, et al. Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. J Natl Compr Canc Netw. 2022 ; 20 (1) : 37–44. DOI: 10.6004/jnccn.2021.7055.</mixed-citation><mixed-citation xml:lang="en">Chow R., Lage D. E., Williams G. R, et al. Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. J Natl Compr Canc Netw. 2022 ; 20 (1) : 37–44. DOI: 10.6004/jnccn.2021.7055.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gomes F., Wong M., Battisti N. M. L., et al. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. Br J Cancer. 2020 ; 123 (6) : 874–884. DOI: 10.1038/s41416-020-0986-4.</mixed-citation><mixed-citation xml:lang="en">Gomes F., Wong M., Battisti N. M. L., et al. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. Br J Cancer. 2020 ; 123 (6) : 874–884. DOI: 10.1038/s41416-020-0986-4.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2024 году / Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. — М. : МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025. — илл. — 275 с.</mixed-citation><mixed-citation xml:lang="en">The state of oncological care for the population of Russia in 2024. Edited by A. D. Kaprin, V. V. Starinsky, A. O. Shakhzadova. 2025. Moscow : P. A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, ill. 275 p. (In Russ.). ISBN 978-5-85502-309-1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">SEER. Cancer Stat Facts: Lung and Bronchus Cancer. Retrieved June 7, 2025, from https://seer.cancer.gov/statfacts/html/lungb.html.</mixed-citation><mixed-citation xml:lang="en">SEER. Cancer Stat Facts: Lung and Bronchus Cancer. Retrieved June 7, 2025, from https://seer.cancer.gov/statfacts/html/lungb.html.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Veronese N., Custodero C., Cella A., et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and metaanalysis. Ageing Res Rev. 2021 ; 72 : 101498. DOI: 10.1016/j.arr.2021.101498.</mixed-citation><mixed-citation xml:lang="en">Veronese N., Custodero C., Cella A., et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and metaanalysis. Ageing Res Rev. 2021 ; 72 : 101498. DOI: 10.1016/j.arr.2021.101498.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Komici K., Bencivenga L., Navani N., et al. Frailty in Patients With Lung Cancer: A Systematic Review and Meta-Analysis. Chest. 2022 ; 162 (2) : 485–497. DOI: 10.1016/j.chest.2022.02.027.</mixed-citation><mixed-citation xml:lang="en">Komici K., Bencivenga L., Navani N., et al. Frailty in Patients With Lung Cancer: A Systematic Review and Meta-Analysis. Chest. 2022 ; 162 (2) : 485–497. DOI: 10.1016/j.chest.2022.02.027.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kim E. E., Cenzer I., Graham F. J., et al. Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis. Am J Prev Med. 2025 ; 69 (2) : 107736. DOI: 10.1016/j.amepre.2025.107736.</mixed-citation><mixed-citation xml:lang="en">Kim E. E., Cenzer I., Graham F. J., et al. Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis. Am J Prev Med. 2025 ; 69 (2) : 107736. DOI: 10.1016/j.amepre.2025.107736.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tang F. H., Wong H. Y. T., Tsang P. S. W., et al. Recent advancements in lung cancer research: a narrative review. Transl Lung Cancer Res. 2025 ; 14 (3) : 975–990. DOI: 10.21037/tlcr-24-979.</mixed-citation><mixed-citation xml:lang="en">Tang F. H., Wong H. Y. T., Tsang P. S. W., et al. Recent advancements in lung cancer research: a narrative review. Transl Lung Cancer Res. 2025 ; 14 (3) : 975–990. DOI: 10.21037/tlcr-24-979.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yao D., Yang S., Wen Z., et al. Influencing factors for multi-dimensional frailty of older adults in community: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2025 ; 137 : 105935. DOI: 10.1016/j.archger.2025.105935.</mixed-citation><mixed-citation xml:lang="en">Yao D., Yang S., Wen Z., et al. Influencing factors for multi-dimensional frailty of older adults in community: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2025 ; 137 : 105935. DOI: 10.1016/j.archger.2025.105935.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Almatrafi A., Thomas O., Callister M., et al. The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis. J Med Screen. 2023 ; 30 (1) : 3–13. DOI: 10.1177/09691413221117685.</mixed-citation><mixed-citation xml:lang="en">Almatrafi A., Thomas O., Callister M., et al. The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis. J Med Screen. 2023 ; 30 (1) : 3–13. DOI: 10.1177/09691413221117685.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tkacheva O. N., Runikhina N. K., Merkusheva L. I., et al. The Association Between Comorbidity, Frailty, and Outdoor Mobility Loss Among Community-Dwelling Individuals 60 Years of Age and Above in Moscow. Rejuvenation Res. 2021 ; 24 (2) : 151–157. DOI: 10.1089/rej.2019.2289.</mixed-citation><mixed-citation xml:lang="en">Tkacheva O. N., Runikhina N. K., Merkusheva L. I., et al. The Association Between Comorbidity, Frailty, and Outdoor Mobility Loss Among Community-Dwelling Individuals 60 Years of Age and Above in Moscow. Rejuvenation Res. 2021 ; 24 (2) : 151–157. DOI: 10.1089/rej.2019.2289.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liu T., Peng X., Geng Y., et al. Frailty and prognosis in lung cancer: systematic review and meta-analysis. BMJ Support Palliat Care. 2024 ; 14 (2) : 121–131. DOI: 10.1136/spcare-2023-004577.</mixed-citation><mixed-citation xml:lang="en">Liu T., Peng X., Geng Y., et al. Frailty and prognosis in lung cancer: systematic review and meta-analysis. BMJ Support Palliat Care. 2024 ; 14 (2) : 121–131. DOI: 10.1136/spcare-2023-004577.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cao X., Yang Z., Li X., et al. Association of frailty with the incidence risk of cardiovascular disease and type 2 diabetes mellitus in long-term cancer survivors: a prospective cohort study. BMC Med. 2023 ; 21 (1) : 74. DOI: 10.1186/s12916-023-02774-1.</mixed-citation><mixed-citation xml:lang="en">Cao X., Yang Z., Li X., et al. Association of frailty with the incidence risk of cardiovascular disease and type 2 diabetes mellitus in long-term cancer survivors: a prospective cohort study. BMC Med. 2023 ; 21 (1) : 74. DOI: 10.1186/s12916-023-02774-1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Muhandiramge J., Orchard S. G., Warner E. T., et al. Functional Decline in the Cancer Patient: A Review. Cancers (Basel). 2022 ; 14 (6) : 1368. DOI: 10.3390/cancers14061368.</mixed-citation><mixed-citation xml:lang="en">Muhandiramge J., Orchard S. G., Warner E. T., et al. Functional Decline in the Cancer Patient: A Review. Cancers (Basel). 2022 ; 14 (6) : 1368. DOI: 10.3390/cancers14061368.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hu J., Lan J., &amp; Xu G. Role of frailty in predicting prognosis of older patients with lung cancer: An updated systematic review and meta-analysis. J Geriatr Oncol. 2024 ; 15 (7) : 101804. DOI: 10.1016/j.jgo.2024.101804.</mixed-citation><mixed-citation xml:lang="en">Hu J., Lan J., &amp; Xu G. Role of frailty in predicting prognosis of older patients with lung cancer: An updated systematic review and meta-analysis. J Geriatr Oncol. 2024 ; 15 (7) : 101804. DOI: 10.1016/j.jgo.2024.101804.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Eruslanova, K. A., Luzina, A. V., Onuchina, Y. S., et al. Influence of risk factors for cardiovascular diseases, history of cardiovascular diseases, and structural and functional state of the heart on 3-year survival in persons 95 years and older. Advances in gerontology = Uspekhi gerontologii. 2021 ; 34 (5) : 727–733. DOI: 10.34922/AE.2021.34.5.009.</mixed-citation><mixed-citation xml:lang="en">Eruslanova, K. A., Luzina, A. V., Onuchina, Y. S., et al. Influence of risk factors for cardiovascular diseases, history of cardiovascular diseases, and structural and functional state of the heart on 3-year survival in persons 95 years and older. Advances in gerontology = Uspekhi gerontologii. 2021 ; 34 (5) : 727–733. DOI: 10.34922/AE.2021.34.5.009.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yan L. C., Lu H. Y., Wang X. Y., et al. Prevalence and risk factors of frailty in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Eur Geriatr Med. 2023 ; 14 (4) : 789–802. DOI: 10.1007/s41999-023-00800-2.</mixed-citation><mixed-citation xml:lang="en">Yan L. C., Lu H. Y., Wang X. Y., et al. Prevalence and risk factors of frailty in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Eur Geriatr Med. 2023 ; 14 (4) : 789–802. DOI: 10.1007/s41999-023-00800-2.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cherian M., Masoudian P., Thavorn K., et al. The impact of frailty on clinical outcomes among individuals with COPD: a systematic review and meta-analysis. BMC Pulm Med. 2025 ; 25 (1) : 146. DOI: 10.1186/s12890-025-03595-z.</mixed-citation><mixed-citation xml:lang="en">Cherian M., Masoudian P., Thavorn K., et al. The impact of frailty on clinical outcomes among individuals with COPD: a systematic review and meta-analysis. BMC Pulm Med. 2025 ; 25 (1) : 146. DOI: 10.1186/s12890-025-03595-z.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao P., Sheng P., Liu H., &amp; Liang H. (2025). Chronic Obstructive Pulmonary Disease and Lung Cancer: A Meta-Analysis of Risk Association. International journal of chronic obstructive pulmonary disease, 20, 3269–3277. DOI: 10.2147/COPD.S539213.</mixed-citation><mixed-citation xml:lang="en">Qiao P., Sheng P., Liu H., &amp; Liang H. (2025). Chronic Obstructive Pulmonary Disease and Lung Cancer: A Meta-Analysis of Risk Association. International journal of chronic obstructive pulmonary disease, 20, 3269–3277. DOI: 10.2147/COPD.S539213.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Obeng-Nyarkoh P. I., Valentin-Figueroa M. E., Cadham C. J., et al. Lung Cancer Risk in US Adults with COPD: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2025 ; 20 : 3399–3421. DOI: 10.2147/COPD.S531972.</mixed-citation><mixed-citation xml:lang="en">Obeng-Nyarkoh P. I., Valentin-Figueroa M. E., Cadham C. J., et al. Lung Cancer Risk in US Adults with COPD: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2025 ; 20 : 3399–3421. DOI: 10.2147/COPD.S531972.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bade B. C., Blasberg J. D., Mase V. J., et al. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablationpart 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. J Thorac Dis. 2022 ; 14 (6) : 2387–2411. DOI: 10.21037/jtd-21-1825.</mixed-citation><mixed-citation xml:lang="en">Bade B. C., Blasberg J. D., Mase V. J., et al. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablationpart 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. J Thorac Dis. 2022 ; 14 (6) : 2387–2411. DOI: 10.21037/jtd-21-1825.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H., Lee E., &amp; Jang I. Y. Frailty and Comprehensive Geriatric Assessment. J Korean Med Sci. 2020 ; 35 (3) : e16. DOI: 10.3346/jkms.2020.35.e16.</mixed-citation><mixed-citation xml:lang="en">Lee H., Lee E., &amp; Jang I. Y. Frailty and Comprehensive Geriatric Assessment. J Korean Med Sci. 2020 ; 35 (3) : e16. DOI: 10.3346/jkms.2020.35.e16.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y., Ji T., Li X., et al. The effectiveness of the comprehensive geriatric assessment for older adults with frailty in hospital settings: A systematic review and metaanalysis. Int J Nurs Stud. 2024 ; 159 : 104849. DOI: 10.1016/j.ijnurstu.2024.104849.</mixed-citation><mixed-citation xml:lang="en">Xu Y., Ji T., Li X., et al. The effectiveness of the comprehensive geriatric assessment for older adults with frailty in hospital settings: A systematic review and metaanalysis. Int J Nurs Stud. 2024 ; 159 : 104849. DOI: 10.1016/j.ijnurstu.2024.104849.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chen R., Yang D., Tian M., et al. The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic review. Oncologist. 2025 ; 30 (6) : oyaf118. DOI: 10.1093/oncolo/oyaf118.</mixed-citation><mixed-citation xml:lang="en">Chen R., Yang D., Tian M., et al. The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic review. Oncologist. 2025 ; 30 (6) : oyaf118. DOI: 10.1093/oncolo/oyaf118.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Cappe M., Laterre P. F., Dechamps M. Preoperative frailty screening, assessment and management. Curr Opin Anaesthesiol. 2023 ; 36 (1) : 83–88. DOI: 10.1097/ACO.0000000000001221.</mixed-citation><mixed-citation xml:lang="en">Cappe M., Laterre P. F., Dechamps M. Preoperative frailty screening, assessment and management. Curr Opin Anaesthesiol. 2023 ; 36 (1) : 83–88. DOI: 10.1097/ACO.0000000000001221.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Wu H., Yan S., Cao H., et al. Unraveling the impact of frailty on postoperative delirium in elderly surgical patients: a systematic review and meta-analysis. BMC Anesthesiol. 2025; (25) : 114. DOI: 10.1186/s12871-025-02994-3.</mixed-citation><mixed-citation xml:lang="en">Wu H., Yan S., Cao H., et al. Unraveling the impact of frailty on postoperative delirium in elderly surgical patients: a systematic review and meta-analysis. BMC Anesthesiol. 2025; (25) : 114. DOI: 10.1186/s12871-025-02994-3.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Luo L., Li J., et al. Prognostic Value of Pretreatment Geriatric Nutrition Risk Index in Lung Cancer Patients: A Meta-Analysis. Nutr Cancer. 2022 ; 74 (9) : 3164–3171. DOI: 10.1080/01635581.2022.2059093.</mixed-citation><mixed-citation xml:lang="en">Wang Y., Luo L., Li J., et al. Prognostic Value of Pretreatment Geriatric Nutrition Risk Index in Lung Cancer Patients: A Meta-Analysis. Nutr Cancer. 2022 ; 74 (9) : 3164–3171. DOI: 10.1080/01635581.2022.2059093.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J., Tang X., Zhang W., et al. Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: A meta-analysis. Clin Nutr. 2024 ; 43 (7) : 1618–1625. DOI: 10.1016/j.clnu.2024.05.025.</mixed-citation><mixed-citation xml:lang="en">Zhang J., Tang X., Zhang W., et al. Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: A meta-analysis. Clin Nutr. 2024 ; 43 (7) : 1618–1625. DOI: 10.1016/j.clnu.2024.05.025.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Nakada T., Suyama Y., Arakawa S., et al. Analysis of postoperative weight loss associated with prognosis after sublobar resections for lung cancer. Gen Thorac Cardiovasc Surg. 2025 ; 73 (3) : 190–197. DOI: 10.1007/s11748-024-02069-z.</mixed-citation><mixed-citation xml:lang="en">Nakada T., Suyama Y., Arakawa S., et al. Analysis of postoperative weight loss associated with prognosis after sublobar resections for lung cancer. Gen Thorac Cardiovasc Surg. 2025 ; 73 (3) : 190–197. DOI: 10.1007/s11748-024-02069-z.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Sun X. Y., Lin Y., Guo W., et al. Prognostic Value of the Geriatric Nutritional Risk Index in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Nutr Cancer. 2022 ; 74 (10) : 3623–3633. DOI: 10.1080/01635581.2022.2096244.</mixed-citation><mixed-citation xml:lang="en">Sun X. Y., Lin Y., Guo W., et al. Prognostic Value of the Geriatric Nutritional Risk Index in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Nutr Cancer. 2022 ; 74 (10) : 3623–3633. DOI: 10.1080/01635581.2022.2096244.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Howington J., Souter L. H., Arenberg D., et al. Management of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025 ; 168 (3) : 810–827. DOI: 10.1016/j.chest.2025.06.023.</mixed-citation><mixed-citation xml:lang="en">Howington J., Souter L. H., Arenberg D., et al. Management of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025 ; 168 (3) : 810–827. DOI: 10.1016/j.chest.2025.06.023.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Jensik R. J., Faber L. P., Milloy F. J., Monson D. O. Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg. 1973 ; 66 (4) : 563–572.</mixed-citation><mixed-citation xml:lang="en">Jensik R. J., Faber L. P., Milloy F. J., Monson D. O. Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg. 1973 ; 66 (4) : 563–572.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ginsberg R. J., &amp; Rubinstein L. V. (1995). Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 ; 60 (3) : 615–623. DOI: 10.1016/0003-4975(95)00537-u.</mixed-citation><mixed-citation xml:lang="en">Ginsberg R. J., &amp; Rubinstein L. V. (1995). Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 ; 60 (3) : 615–623. DOI: 10.1016/0003-4975(95)00537-u.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Баксиян Г. А., Завьялов А. А. Актуальность и оправданность сублобарной резекции при раннем периферическом немелкоклеточном раке легкого в Эру господства лобэктомии (обзор литературы) // Практическая онкология. — 2023. — Т. 24, № 2. — С. 185–193</mixed-citation><mixed-citation xml:lang="en">Baksiyan G. A., Zavyalov A. A. Relevance and justification of sublobar resection in early peripheral non-small cell lung cancer in the Era of dominance of lobectomy (literature review). Practical Oncology. 2023 ; 24 (2) : 185–193 (In Russ.). DOI: 10.31917/2402185.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Magouliotis D. E., Cioffi U., Minervini F., et al. Changes in quality of life of early-stage lung cancer patients undergoing sublobar resection: a systematic review. Front Surg. 2025 ; 12 : 1542036. DOI: 10.3389/fsurg.2025.1542036.</mixed-citation><mixed-citation xml:lang="en">Magouliotis D. E., Cioffi U., Minervini F., et al. Changes in quality of life of early-stage lung cancer patients undergoing sublobar resection: a systematic review. Front Surg. 2025 ; 12 : 1542036. DOI: 10.3389/fsurg.2025.1542036.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Altorki N., Wang X., Kozono D., et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 ; 388 (6) : 489–498. DOI: 10.1056/NEJMoa2212083.</mixed-citation><mixed-citation xml:lang="en">Altorki N., Wang X., Kozono D., et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 ; 388 (6) : 489–498. DOI: 10.1056/NEJMoa2212083.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Tasoudis P., Loufopoulos G., Manaki V., et al. Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis. Lung Cancer. 2024 ; 195 : 107929. DOI: 10.1016/j.lungcan.2024.107929.</mixed-citation><mixed-citation xml:lang="en">Tasoudis P., Loufopoulos G., Manaki V., et al. Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis. Lung Cancer. 2024 ; 195 : 107929. DOI: 10.1016/j.lungcan.2024.107929.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Kato H., Nakamura H., Tsuboi M., et al. Treatment of peripheral early stage lung cancer. Ann Thorac Cardiovasc Surg. 2004 ; 10 (1) : 1–3.</mixed-citation><mixed-citation xml:lang="en">Kato H., Nakamura H., Tsuboi M., et al. Treatment of peripheral early stage lung cancer. Ann Thorac Cardiovasc Surg. 2004 ; 10 (1) : 1–3.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Akinoso-Imran A. Q., O'Rorke M., Kee F., et al. Surgical under-treatment of older adult patients with cancer: A systematic review and meta-analysis. J Geriatr Oncol. 2022 ; 13 (4) : 398–409. DOI: 10.1016/j.jgo.2021.11.004.</mixed-citation><mixed-citation xml:lang="en">Akinoso-Imran A. Q., O'Rorke M., Kee F., et al. Surgical under-treatment of older adult patients with cancer: A systematic review and meta-analysis. J Geriatr Oncol. 2022 ; 13 (4) : 398–409. DOI: 10.1016/j.jgo.2021.11.004.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ng J., Masuda Y., Ng J. J., et al. Lobar versus Sublobar Resection in the Elderly for Early Lung Cancer: A Meta-Analysis. Thorac Cardiovasc Surg. 2022 ; 70 (3) : 217–232. DOI: 10.1055/s-0041-1726100.</mixed-citation><mixed-citation xml:lang="en">Ng J., Masuda Y., Ng J. J., et al. Lobar versus Sublobar Resection in the Elderly for Early Lung Cancer: A Meta-Analysis. Thorac Cardiovasc Surg. 2022 ; 70 (3) : 217–232. DOI: 10.1055/s-0041-1726100.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Mamede I., Ribeiro L., Stecca C., et al. Survival and pulmonary function in stage IA non-small cell lung cancer after sublobar resection versus lobectomy: An updated metaanalysis. J Surg Oncol. 2024 ; 130 (3) : 523–532. DOI: 10.1002/jso.27767.</mixed-citation><mixed-citation xml:lang="en">Mamede I., Ribeiro L., Stecca C., et al. Survival and pulmonary function in stage IA non-small cell lung cancer after sublobar resection versus lobectomy: An updated metaanalysis. J Surg Oncol. 2024 ; 130 (3) : 523–532. DOI: 10.1002/jso.27767.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Lin H., Peng Z., Zhou K., et al. Differential efficacy of segmentectomy and wedge resection in sublobar resection compared to lobectomy for solid-dominant stage IA lung cancer: a systematic review and meta-analysis. Int J Surg. 2024 ; 110 (2) : 1159–1171. DOI: 10.1097/JS9.0000000000000896.</mixed-citation><mixed-citation xml:lang="en">Lin H., Peng Z., Zhou K., et al. Differential efficacy of segmentectomy and wedge resection in sublobar resection compared to lobectomy for solid-dominant stage IA lung cancer: a systematic review and meta-analysis. Int J Surg. 2024 ; 110 (2) : 1159–1171. DOI: 10.1097/JS9.0000000000000896.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Li S., Ge Y., Ma R., et al. Comparison of Wedge Resection and Anatomical Lung Resection in Elderly Patients With Early-Stage Nonsmall Cell Lung Cancer With Visceral Pleural Invasion: A Population-Based Study. Thorac Cancer. 2025 ; 16 (3): e15532. DOI: 10.1111/1759-7714.15532.</mixed-citation><mixed-citation xml:lang="en">Li S., Ge Y., Ma R., et al. Comparison of Wedge Resection and Anatomical Lung Resection in Elderly Patients With Early-Stage Nonsmall Cell Lung Cancer With Visceral Pleural Invasion: A Population-Based Study. Thorac Cancer. 2025 ; 16 (3): e15532. DOI: 10.1111/1759-7714.15532.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Z., Feng H., Zhao H., et al. Sublobar resection is associated with better perioperative outcomes in elderly patients with clinical stage I non-small cell lung cancer: a multicenter retrospective cohort study. J Thorac Dis. 2019 ; 11 (5) : 1838–1848. DOI: 10.21037/jtd.2019.05.20.</mixed-citation><mixed-citation xml:lang="en">Zhang Z., Feng H., Zhao H., et al. Sublobar resection is associated with better perioperative outcomes in elderly patients with clinical stage I non-small cell lung cancer: a multicenter retrospective cohort study. J Thorac Dis. 2019 ; 11 (5) : 1838–1848. DOI: 10.21037/jtd.2019.05.20.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Dong S., Roberts S. A., Chen S., et al. Survival after lobectomy versus sub-lobar resection in elderly with stage I NSCLC: a meta-analysis BMC Surg. 2019 ; 19 (1) : 38. DOI: 10.1186/s12893-019-0500-1.</mixed-citation><mixed-citation xml:lang="en">Dong S., Roberts S. A., Chen S., et al. Survival after lobectomy versus sub-lobar resection in elderly with stage I NSCLC: a meta-analysis BMC Surg. 2019 ; 19 (1) : 38. DOI: 10.1186/s12893-019-0500-1.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Salazar M. C., Canavan M. E., Walters S. L., et al. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clin Res Rep. 2021 ; 2 (3) : 100143. DOI: 10.1016/j.jtocrr.2021.100143.</mixed-citation><mixed-citation xml:lang="en">Salazar M. C., Canavan M. E., Walters S. L., et al. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clin Res Rep. 2021 ; 2 (3) : 100143. DOI: 10.1016/j.jtocrr.2021.100143.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Zhu H., Luo N., et al. Optimizing lung cancer surgery in the elderly: sublobar resection versus lobectomy for early-stage non-small cell lung cancer patients aged 80 and above. Discov Oncol. 2024 ; 15 (1) : 585. DOI: 10.1007/s12672-024-01468-1.</mixed-citation><mixed-citation xml:lang="en">Li J., Zhu H., Luo N., et al. Optimizing lung cancer surgery in the elderly: sublobar resection versus lobectomy for early-stage non-small cell lung cancer patients aged 80 and above. Discov Oncol. 2024 ; 15 (1) : 585. DOI: 10.1007/s12672-024-01468-1.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Meldola P. F., Toth O. A. S., Schnorrenberger E., et al. Sublobar resection versus lobectomy for stage IA non-smallcell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Surg Oncol. 2023 ; 51 : 101995. DOI: 10.1016/j.suronc.2023.101995.</mixed-citation><mixed-citation xml:lang="en">Meldola P. F., Toth O. A. S., Schnorrenberger E., et al. Sublobar resection versus lobectomy for stage IA non-smallcell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Surg Oncol. 2023 ; 51 : 101995. DOI: 10.1016/j.suronc.2023.101995.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Saji H., Okada M., Tsuboi M., et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, openlabel, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022 ; 399 (10335) : 1607–1617. DOI: 10.1016/S0140-6736(21)02333-3.</mixed-citation><mixed-citation xml:lang="en">Saji H., Okada M., Tsuboi M., et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, openlabel, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022 ; 399 (10335) : 1607–1617. DOI: 10.1016/S0140-6736(21)02333-3.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Wang Y., Li J., et al. Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces. Clin Lung Cancer. 2022 ; 23 (3) : 208–213. DOI: 10.1016/j.cllc.2021.10.004.</mixed-citation><mixed-citation xml:lang="en">Li J., Wang Y., Li J., et al. Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces. Clin Lung Cancer. 2022 ; 23 (3) : 208–213. DOI: 10.1016/j.cllc.2021.10.004.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Баксиян Г. А., Завьялов А. А., Восканян С. Э., Лищук С. В. STAS — четвертый механизм инвазии злокачественных опухолей легкого. Влияние на результаты лечения // Онкология. Журнал им. П. А. Герцена. — 2025. — Т. 14, № 3. — С. 79–84.</mixed-citation><mixed-citation xml:lang="en">Baksiyan G. A., Zavialov A. A., Voskanyan S. E., Lishuk S. V. STAS — the fourth mechanism of invasion of malignant lung tumors. Impact on treatment outcomes. P. A. Herzen Journal of Oncology. 2025 ; 14 (3) : 79–84. (In Russ.). DOI: 10.17116/onkolog20251403194.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J., Ni H., Wu Y., et al. Perioperative comparison of video-assisted thoracic surgery and open lobectomy for pT1-stage non-small cell lung cancer patients in China: a multicenter propensity score-matched analysis. Transl Lung Cancer Res. 2021 ; 10 (1) : 402–414. DOI: 10.21037/tlcr-20-1132.</mixed-citation><mixed-citation xml:lang="en">Xu J., Ni H., Wu Y., et al. Perioperative comparison of video-assisted thoracic surgery and open lobectomy for pT1-stage non-small cell lung cancer patients in China: a multicenter propensity score-matched analysis. Transl Lung Cancer Res. 2021 ; 10 (1) : 402–414. DOI: 10.21037/tlcr-20-1132.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S., Noh O. K. Comparison of surgery and stereotactic body radiation therapy for clinical stage I NSCLC: a propensity score-matched analysis from a single institution. J Thorac Dis. 2025 ; 17 (9) : 6884–6892. DOI: 10.21037/jtd-2025-925.</mixed-citation><mixed-citation xml:lang="en">Lee S., Noh O. K. Comparison of surgery and stereotactic body radiation therapy for clinical stage I NSCLC: a propensity score-matched analysis from a single institution. J Thorac Dis. 2025 ; 17 (9) : 6884–6892. DOI: 10.21037/jtd-2025-925.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Wu G. J., Zhang Y., Liang R., et al. Comparison of Survival Outcomes of Early-Stage Non-Small-Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection. World J Surg. 2025 ; 49 (5) : 1160–1171. DOI: 10.1002/wjs.12584.</mixed-citation><mixed-citation xml:lang="en">Wu G. J., Zhang Y., Liang R., et al. Comparison of Survival Outcomes of Early-Stage Non-Small-Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection. World J Surg. 2025 ; 49 (5) : 1160–1171. DOI: 10.1002/wjs.12584.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Hua W., Zhang Z., Ni L., &amp; Liu X. Comparison of surgical and radiotherapy outcomes in octogenarians with early-stage non-small cell lung cancer: a SEER database retrospective cohort study. Aging Clin Exp Res. 2025 ; 37 (1) : 53. DOI: 10.1007/s40520-025-02948-2.</mixed-citation><mixed-citation xml:lang="en">Hua W., Zhang Z., Ni L., &amp; Liu X. Comparison of surgical and radiotherapy outcomes in octogenarians with early-stage non-small cell lung cancer: a SEER database retrospective cohort study. Aging Clin Exp Res. 2025 ; 37 (1) : 53. DOI: 10.1007/s40520-025-02948-2.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Feigenberg S. J., Costabile F., Tanes C., et al. Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. J Immunother Cancer. 2025 ; 13 (7) : e011356. DOI: 10.1136/jitc-2024-011356.</mixed-citation><mixed-citation xml:lang="en">Feigenberg S. J., Costabile F., Tanes C., et al. Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. J Immunother Cancer. 2025 ; 13 (7) : e011356. DOI: 10.1136/jitc-2024-011356.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Saad M. B., Showkatian E., Verma V., et al. Causal AIbased clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in earlystage NSCLC: a secondary analysis of the phase II I-SABR trial. J Immunother Cancer. 2025 ; 13 (10) : e013074. DOI: 10.1136/jitc-2025-013074.</mixed-citation><mixed-citation xml:lang="en">Saad M. B., Showkatian E., Verma V., et al. Causal AIbased clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in earlystage NSCLC: a secondary analysis of the phase II I-SABR trial. J Immunother Cancer. 2025 ; 13 (10) : e013074. DOI: 10.1136/jitc-2025-013074.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Chin V., Chlap P., Finnegan R., et al. Cardiac Substructure Dose and Survival in Stereotactic Radiotherapy for Lung Cancer: Results of the Multi-Centre SSBROC Trial. Clin Oncol (R Coll Radiol). 2024 ; 36 (10) : 642–650. DOI: 10.1016/j.clon.2024.07.005.</mixed-citation><mixed-citation xml:lang="en">Chin V., Chlap P., Finnegan R., et al. Cardiac Substructure Dose and Survival in Stereotactic Radiotherapy for Lung Cancer: Results of the Multi-Centre SSBROC Trial. Clin Oncol (R Coll Radiol). 2024 ; 36 (10) : 642–650. DOI: 10.1016/j.clon.2024.07.005.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Ding Q., Wang C., Zhang Z., et al. An explainable AI approach to surgical and radiotherapy interventions for optimized treatment decision-making in early-stage nonsmall cell lung cancer. Transl Lung Cancer Res. 2025 ; 14 (6) : 2011–2030. DOI: 10.21037/tlcr-2025-152.</mixed-citation><mixed-citation xml:lang="en">Ding Q., Wang C., Zhang Z., et al. An explainable AI approach to surgical and radiotherapy interventions for optimized treatment decision-making in early-stage nonsmall cell lung cancer. Transl Lung Cancer Res. 2025 ; 14 (6) : 2011–2030. DOI: 10.21037/tlcr-2025-152.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Arriagada R., Bergman B., Dunant A., et al. Cisplatinbased adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 ; 350 (4) : 351–360. DOI: 10.1056/NEJMoa031644.</mixed-citation><mixed-citation xml:lang="en">Arriagada R., Bergman B., Dunant A., et al. Cisplatinbased adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 ; 350 (4) : 351–360. DOI: 10.1056/NEJMoa031644.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Felip E., Altorki N., Zhou C., et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 ; 398 (10308) : 1344–1357. DOI: 10.1016/S0140-6736(21)02098-5.</mixed-citation><mixed-citation xml:lang="en">Felip E., Altorki N., Zhou C., et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 ; 398 (10308) : 1344–1357. DOI: 10.1016/S0140-6736(21)02098-5.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">O'Brien M., Paz-Ares L., Marreaud S., et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 ; 23 (10) : 1274–1286. DOI: 10.1016/S1470-2045(22)00518-6.</mixed-citation><mixed-citation xml:lang="en">O'Brien M., Paz-Ares L., Marreaud S., et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 ; 23 (10) : 1274–1286. DOI: 10.1016/S1470-2045(22)00518-6.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Spigel D. R., Westeel V., Anderson I. C., et al. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. Lancet Respir Med. 2025 ; 13 (10) : 887–896. DOI: 10.1016/S2213-2600(25)00213-9.</mixed-citation><mixed-citation xml:lang="en">Spigel D. R., Westeel V., Anderson I. C., et al. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. Lancet Respir Med. 2025 ; 13 (10) : 887–896. DOI: 10.1016/S2213-2600(25)00213-9.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Yin J., Song Y., Fu Y., et al. The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis. Aging (Albany NY). 2023 ; 15 (24) : 15025–15049. DOI: 10.18632/aging.205328.</mixed-citation><mixed-citation xml:lang="en">Yin J., Song Y., Fu Y., et al. The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis. Aging (Albany NY). 2023 ; 15 (24) : 15025–15049. DOI: 10.18632/aging.205328.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
